BeiGene to Present at Upcoming Investor Conferences
BeiGene, (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company planning to rebrand as BeOne Medicines , has announced its participation in two upcoming investor conferences.
The company will engage in fireside chats at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 9:10 am ET, and the Leerink Partners Global Biopharma Conference on Monday, March 10, 2025, at 1:00 pm ET.
Investors can access live webcasts of both events through BeiGene's investor relations websites. Archived replays will remain available for 90 days following each conference.
BeiGene, (NASDAQ: ONC; HKEX: 06160; SSE: 688235), una compagnia globale nel settore oncologico che prevede di cambiare nome in BeOne Medicines, ha annunciato la sua partecipazione a due prossimi conferenze per investitori.
L'azienda parteciperà a discussioni informali durante la 45ª Conferenza Annuale sulla Salute di TD Cowen lunedì 3 marzo 2025, alle 9:10 ET, e alla Conferenza Globale Biopharma di Leerink Partners lunedì 10 marzo 2025, alle 13:00 ET.
Gli investitori possono accedere alle trasmissioni in diretta di entrambi gli eventi attraverso i siti web delle relazioni con gli investitori di BeiGene. Le registrazioni archiviate saranno disponibili per 90 giorni dopo ciascuna conferenza.
BeiGene, (NASDAQ: ONC; HKEX: 06160; SSE: 688235), una empresa global de oncología que planea cambiar su nombre a BeOne Medicines, ha anunciado su participación en dos próximas conferencias para inversores.
La compañía participará en charlas informales en la 45ª Conferencia Anual de Atención Médica de TD Cowen el lunes 3 de marzo de 2025, a las 9:10 am ET, y en la Conferencia Global de Biopharma de Leerink Partners el lunes 10 de marzo de 2025, a la 1:00 pm ET.
Los inversores pueden acceder a las transmisiones en vivo de ambos eventos a través de los sitios web de relaciones con inversores de BeiGene. Las repeticiones archivadas estarán disponibles durante 90 días después de cada conferencia.
BeiGene, (NASDAQ: ONC; HKEX: 06160; SSE: 688235), BeOne Medicines로 브랜드를 변경할 계획인 글로벌 종양학 회사가 두 개의 투자자 회의에 참여한다고 발표했습니다.
회사는 2025년 3월 3일 월요일 오전 9시 10분 ET에 TD Cowen 제45회 연례 의료 회의와 2025년 3월 10일 월요일 오후 1시 ET에 Leerink Partners 글로벌 바이오파마 회의에서 화상 대화에 참여할 예정입니다.
투자자는 BeiGene의 투자자 관계 웹사이트를 통해 두 이벤트의 실시간 웹캐스트에 접근할 수 있습니다. 각 회의 후 90일 동안 아카이브된 재생이 제공됩니다.
BeiGene, (NASDAQ: ONC; HKEX: 06160; SSE: 688235), une entreprise mondiale en oncologie qui prévoit de se renommer BeOne Medicines, a annoncé sa participation à deux prochaines conférences pour investisseurs.
L'entreprise participera à des discussions informelles lors de la 45e Conférence Annuelle sur la Santé de TD Cowen le lundi 3 mars 2025, à 9h10 ET, et à la Conférence Biopharma Mondiale de Leerink Partners le lundi 10 mars 2025, à 13h00 ET.
Les investisseurs peuvent accéder aux webdiffusions en direct des deux événements via les sites web des relations avec les investisseurs de BeiGene. Les rediffusions archivées resteront disponibles pendant 90 jours après chaque conférence.
BeiGene, (NASDAQ: ONC; HKEX: 06160; SSE: 688235), ein globales Onkologieunternehmen, das plant, sich in BeOne Medicines umzubenennen, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben.
Das Unternehmen wird an informellen Gesprächen auf der 45. jährlichen Gesundheitskonferenz von TD Cowen am Montag, den 3. März 2025, um 9:10 Uhr ET, und der Global Biopharma-Konferenz von Leerink Partners am Montag, den 10. März 2025, um 13:00 Uhr ET teilnehmen.
Investoren können über die Investor Relations-Websites von BeiGene auf die Live-Übertragungen beider Veranstaltungen zugreifen. Archivierte Wiederholungen sind 90 Tage nach jeder Konferenz verfügbar.
- None.
- None.
- TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 am ET; and
- Leerink Partners Global Biopharma Conference on Monday, March 10, 2025 at 1:00 pm ET
Live webcasts of these events can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. Archived replays will be available for 90 days following the events.
About BeiGene
BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 11,000 colleagues spans six continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
These presentations may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's plans, commitments, aspirations and goals related to BeiGene’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeiGene’s most recent periodic report filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225814388/en/
Investors:
Liza Heapes
+1 857-302-5663
ir@beigene.com
Media:
Kyle Blankenship
+1 667-351-5176
media@beigene.com
Source: BeiGene
FAQ
When is BeiGene (ONC) presenting at the TD Cowen Health Care Conference in 2025?
What is BeiGene's new company name going to be?
How long will the webcasts of BeiGene's (ONC) investor conferences be available?
Where can investors access BeiGene's (ONC) conference presentations in March 2025?
What time is BeiGene (ONC) presenting at the Leerink Partners Conference on March 10, 2025?
